ReviewACS chemical neuroscience2019
Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases.
Review in ACS chemical neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 54 citations in OpenAlex.
- In-depth multimodal validation ofExperimental & molecular medicine · 2026Article
- Trifluoromethylation of alkyl electrophiles withScience (New York, N.Y.) · 2025Article
- IND-Enabling Preclinical Studies of [Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2025Article
- Kinetic and quantitative analysis of [Annals of nuclear medicine · 2025Article
- IND-Enabling Preclinical Studies of [11C]COU, a Trapped Metabolite PET Radiotracer for Monoamine Oxidase-B.Research square · 2025Article
- Preclinical evaluation of anEJNMMI radiopharmacy and chemistry · 2024Article
- Molecular Imaging of Monoamine Oxidase A Expression in Highly Aggressive Prostate Cancer: Synthesis and Preclinical Evaluation of Positron Emission Tomography Tracers.ACS pharmacology & translational science · 2023Article
- Peering into the Brain's Estrogen Receptors: PET Tracers for Visualization of Nuclear and Extranuclear Estrogen Receptors in Brain Disorders.Biomolecules · 2023Article
- PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [ACS chemical neuroscience · 2023Article
- Positron Emission Tomography of Neuroimmune Responses in Humans: Insights and Intricacies.Seminars in nuclear medicine · 2023Review
- Effect of MAOA DNA Methylation on Human in Vivo Protein Expression Measured by [11C]harmine Positron Emission Tomography.The international journal of neuropsychopharmacology · 2023Article
- Article
- PET imaging of reactive astrocytes in neurological disorders.European journal of nuclear medicine and molecular imaging · 2022Review
- Imaging of Reactive Astrogliosis by Positron Emission Tomography.Frontiers in neuroscience · 2022Review
- Characterization of neuroinflammatory positron emission tomography biomarkers in chronic traumatic encephalopathy.Brain communications · 2022Article
- Novel brain PET imaging agents: Strategies for imaging neuroinflammation in Alzheimer's disease and mild cognitive impairment.Frontiers in immunology · 2022Review
- Imaging Biomarkers for Monitoring the Inflammatory Redox Landscape in the Brain.Antioxidants (Basel, Switzerland) · 2021Review
- Review
- PET Imaging of Neuroinflammation in Alzheimer's Disease.Frontiers in immunology · 2021Review
- Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B.ACS chemical neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
In this Viewpoint, we highlight the history of positron emission tomography (PET) radiotracer development to quantify changes in monoamine oxidase (MAO)-A and -B enzyme expression or activity. MAO-A and MAO-B are critical for understanding monoaminergic pathways in psychiatric addiction disorders, and more recently in neurodegenerative disorders with MAO-B expression in astrogliosis. Unique radiochemical innovations have been shown for neuroimaging of MAOs including the clinical translation of irreversible propargylamine-based suicide inhibitors, application of deuterium-substitution to slow down metabolism, development of trapped metabolite imaging agents, and unique
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.